Table 1.
Experiment # | Readout | Model | Cellular target | Genotype/AAV | Group | Age (weeks) | Mouse # |
---|---|---|---|---|---|---|---|
1 | Vascular structure |
DGC-Pten KO |
≈20% of dentate granule cells |
Gli1-CreERT2+/−, Ptenwt/wt, TdTomfl/wt |
Control | 4 | 6 (3 F, 3 M) |
Gli1-CreERT2+/−, Ptenwt/wt, TdTomfl/wt |
Control | 6 | 7 (2 F, 5 M) | ||||
Gli1-CreERT2+/−, Ptenwt/wt, TdTomfl/wt |
Control | 10 | 6 (3 F, 3 M) | ||||
Gli1-CreERT2+/−, Ptenfl/fl, TdTomfl/wt |
KO | 4 | 7 (2 F, 5 M) | ||||
Gli1-CreERT2+/−, Ptenfl/fl, TdTomfl/wt |
KO | 6 | 8 (4 F, 4 M) | ||||
Gli1-CreERT2+/−, Ptenfl/fl, TdTomfl/wt |
KO | 10 | 11 (5 F,6 M) | ||||
2 | BBB Integrity | DGC-Pten KO |
≈20% of dentate granule cells |
Gli1-CreERT2−/−, Ptenfl/fl, tdTomwt/wt |
Control | 11 | 3 (3 F, 0 M) |
Gli1-CreERT2−/−, Ptenfl/fl, tdTomfl/wt |
Control | 11 | 2 (1 F, 1 M) | ||||
Gli1-CreERT2+/−, Ptenfl/fl, tdTomwt/wt |
KO | 11 | 4 (3 F, 1 M) | ||||
3 | Vascular structure |
FB-Pten KO |
Forebrain excitatory neurons |
CamK2α-Cre−/−, Ptenfl/fl (or Ptenfl/wt) |
Control | 6.5–7 | 4 (3 F, 1 M) |
CamK2α-Cre+/−, Ptenwt/wt | Control | 6.5–7 | 3 (2 F, 1 M) | ||||
CamK2α-Cre+/−, Ptenfl/fl | KO | 6.5–7 | 5 (3 F, 2 M) | ||||
4 | Western blotting |
FB-Pten KO |
Forebrain excitatory neurons |
CamK2α-Cre−/−, Ptenfl/fl | Control | 7–8 | 2 (1 F, 1 M) |
CamK2α-Cre+/−, Ptenwt/wt | Control | 7–8 | 5 (3 F, 2 M) | ||||
CamK2α-Cre+/−, Ptenfl/fl | KO | 7–8 | 7 (4 F, 3 M) | ||||
5 | Vascular structure |
f-Tsc2 KO |
Focal loss from cortical excitatory neurons |
Tsc2wt/wt + AAV9-CaMKII- mCherry-Cre |
Control | 7, 15, 17, 20 | 4 (2 F, 2 M) |
Tsc2fl/fl + AAV9-CaMKII- mCherry-Cre |
KO | 9, 14, 14,15,19 | 5 (3 F, 2 M) |
Experiment #1, DyLight 649 treatment of DGC-Pten KOs and controls to examine vascular structure. Experiment #2, AF488-BSA treatment of DGC-Pten KOs to assess blood-brain barrier permeability. Experiment #3, DyLight 649 treatment of FB-Pten KOs and controls to examine vascular structure. Experiment #4, Western blot analyses of FB-Pten KOs and controls. Experiment #5; CD31 immunostaining of focal Tsc2 KO mice to examine vascular structure.